Institute of Pharmaceutical Medicine (ECPM)

Research focus:

ECPM’s research focuses on the health economic characteristics, cost-benefit implications and efficient use (e.g. guided by predictive testing or risk stratification models) of pharmaceuticals and other healthcare interventions in Switzerland and internationally. These activities have a close relationship with modern Health Technology Assessment and imply the use and integration of health economic and pharmacoeconomic evaluation methodology (cost effectiveness, cost utility, application of advanced modelling techniques), outcomes and clinical research methodology and biostatistics. Complementary activities occur in related fields such as health systems research, health services research and drug-related clinical epidemiology.


Cooperation and networking:

The research group at ECPM has continuous national collaborations with the Swiss Group for Clinical Cancer Research (SAKK; and the Epidemiology, Biostatistics and Prevention Institute of the University of Zürich. Additional national and international collaborations are multifold but, to date, mostly on a by-project basis, i.e. not institutionalized.


Publications (full publication records:

  • Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting. Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152.
  • Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PLoS One. 2015 May 14;10(5):e0126984. doi: 10.1371/journal.pone.0126984. eCollection 2015.
  • Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M. Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics 2015;33:179-190
  • Pfeil AM, Vulsteke C, Paridaens R, Dieudonné AS, Pettengell R, Hatse S, Neven P, Lambrechts D, Szucs TD, Schwenkglenks M, Wildiers H. Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. BMC Cancer. 2014 Mar 19;14:201. doi: 10.1186/1471-2407-14-201.
  • Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-Gorr K, Szucs T, Pestalozzi BC, Schwenkglenks M. Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons: SAKK 89/09. Oncology. 2014 Sep 26;88(1):18-27.
  • Schwenkglenks M, Gerbershagen HJ, Taylor RS, Pogatzki-Zahn E, Komann M, Rothaug J, Volk T, Yahiaoui-Doktor M, Zaslansky R, Brill S, Ullrich K, Gordon DB, Meissner W. Correlates of satisfaction with pain treatment in the acute postoperative period: Results from the international PAIN OUT registry. Pain. 2014;155:1401-1411.
  • Gutzwiller F, Biller-Andorno N, Harnacke C, Bollhalder L, Szucs T, Gutzwiller F, Schwenkglenks M. Methoden zur Bestimmung von Nutzen bzw. medizinischer Leistungen. Bern: Akademien der Wissenschaften Schweiz 2012. ISBN 978-3-905870-25-1.
  • Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart 2012;98:544-551.
  • Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011;17(19):6338-46.
  • Schwenkglenks M, Brazier JE, Szucs TD, Fox KAA. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health 2011;14:24-33.